KR102712565B1 - Gabaa 수용체 리간드 - Google Patents

Gabaa 수용체 리간드 Download PDF

Info

Publication number
KR102712565B1
KR102712565B1 KR1020217006185A KR20217006185A KR102712565B1 KR 102712565 B1 KR102712565 B1 KR 102712565B1 KR 1020217006185 A KR1020217006185 A KR 1020217006185A KR 20217006185 A KR20217006185 A KR 20217006185A KR 102712565 B1 KR102712565 B1 KR 102712565B1
Authority
KR
South Korea
Prior art keywords
compound
gaba
rats
pharmaceutical composition
itching
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217006185A
Other languages
English (en)
Korean (ko)
Other versions
KR20210061338A (ko
Inventor
야누스 에스. 라센
디팍 암룻카
토마스 에이모스 야콥센
티노 다이링
카린 샌대저 닐슨
Original Assignee
사니오나 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사니오나 에이/에스 filed Critical 사니오나 에이/에스
Publication of KR20210061338A publication Critical patent/KR20210061338A/ko
Application granted granted Critical
Publication of KR102712565B1 publication Critical patent/KR102712565B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217006185A 2018-09-13 2019-09-13 Gabaa 수용체 리간드 Active KR102712565B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18194297.0 2018-09-13
EP18194297 2018-09-13
PCT/EP2019/074465 WO2020053377A1 (en) 2018-09-13 2019-09-13 A gabaa receptor ligand

Publications (2)

Publication Number Publication Date
KR20210061338A KR20210061338A (ko) 2021-05-27
KR102712565B1 true KR102712565B1 (ko) 2024-10-02

Family

ID=63579205

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217006185A Active KR102712565B1 (ko) 2018-09-13 2019-09-13 Gabaa 수용체 리간드

Country Status (24)

Country Link
US (1) US11396510B2 (https=)
EP (1) EP3849976B1 (https=)
JP (1) JP7353663B2 (https=)
KR (1) KR102712565B1 (https=)
CN (1) CN112714765B (https=)
AU (1) AU2019338236B2 (https=)
BR (1) BR112021004661A2 (https=)
CA (1) CA3110283A1 (https=)
DK (1) DK3849976T3 (https=)
EA (1) EA202190717A1 (https=)
ES (1) ES2935705T3 (https=)
FI (1) FI3849976T3 (https=)
HR (1) HRP20230067T1 (https=)
HU (1) HUE060943T2 (https=)
IL (1) IL281335B2 (https=)
LT (1) LT3849976T (https=)
MX (1) MX2021003010A (https=)
PH (1) PH12021550299A1 (https=)
PL (1) PL3849976T3 (https=)
PT (1) PT3849976T (https=)
SG (1) SG11202101360VA (https=)
SI (1) SI3849976T1 (https=)
WO (1) WO2020053377A1 (https=)
ZA (1) ZA202100976B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4322955A1 (en) 2021-04-16 2024-02-21 Saniona A/S A gaba receptor modulator for use in the treatment of pain
WO2025056751A1 (en) * 2023-09-15 2025-03-20 Saniona A/S A gaba receptor modulator for use in the treatment of absence seizures
CN121793969A (zh) * 2023-09-15 2026-04-03 萨尼奥纳有限责任公司 一种用于治疗与睡眠纺锤波缺陷相关的疾病的gaba受体调节剂

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034923A1 (en) 1997-02-07 1998-08-13 Merck Sharp & Dohme Limited Phenylbenzimidazole derivatives as ligands for gaba receptors
WO1999067245A1 (en) 1998-06-24 1999-12-29 Merck Sharp & Dohme Limited A substituted triazolo-pyridazine derivative, pharmaceutical compositions made therefrom
WO2000044752A1 (en) 1999-01-27 2000-08-03 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for gaba receptors
WO2003086406A1 (en) 2002-04-11 2003-10-23 Merck Sharp & Dohme Limited Imidazo-pyridine derivatives as ligands for gaba receptors
WO2007110374A1 (en) 2006-03-24 2007-10-04 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
US10786513B2 (en) 2016-01-27 2020-09-29 Universitat Zurich Use of GABAA receptor modulators for treatment of itch

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675484B2 (en) 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
GB9921150D0 (en) 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
GB0208392D0 (en) 2002-04-11 2002-05-22 Merck Sharp & Dohme Therapeutic compounds
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
WO2004087690A2 (en) 2003-04-03 2004-10-14 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gaba-a receptor complex
TW201029986A (en) 2008-11-14 2010-08-16 Neurosearch As Novel compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034923A1 (en) 1997-02-07 1998-08-13 Merck Sharp & Dohme Limited Phenylbenzimidazole derivatives as ligands for gaba receptors
WO1999067245A1 (en) 1998-06-24 1999-12-29 Merck Sharp & Dohme Limited A substituted triazolo-pyridazine derivative, pharmaceutical compositions made therefrom
WO2000044752A1 (en) 1999-01-27 2000-08-03 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for gaba receptors
WO2003086406A1 (en) 2002-04-11 2003-10-23 Merck Sharp & Dohme Limited Imidazo-pyridine derivatives as ligands for gaba receptors
WO2007110374A1 (en) 2006-03-24 2007-10-04 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
US10786513B2 (en) 2016-01-27 2020-09-29 Universitat Zurich Use of GABAA receptor modulators for treatment of itch

Also Published As

Publication number Publication date
JP2022500445A (ja) 2022-01-04
AU2019338236A1 (en) 2021-05-20
EP3849976B1 (en) 2022-10-26
US11396510B2 (en) 2022-07-26
JP7353663B2 (ja) 2023-10-02
DK3849976T3 (da) 2023-01-23
IL281335B1 (en) 2024-03-01
IL281335A (en) 2021-04-29
EA202190717A1 (ru) 2021-09-22
LT3849976T (lt) 2023-02-10
CN112714765A (zh) 2021-04-27
PH12021550299A1 (en) 2021-10-25
HUE060943T2 (hu) 2023-04-28
PT3849976T (pt) 2023-01-13
FI3849976T3 (fi) 2023-02-19
WO2020053377A1 (en) 2020-03-19
SG11202101360VA (en) 2021-03-30
PL3849976T3 (pl) 2023-02-27
CN112714765B (zh) 2023-06-30
IL281335B2 (en) 2024-07-01
CA3110283A1 (en) 2020-03-19
US20210332042A1 (en) 2021-10-28
EP3849976A1 (en) 2021-07-21
MX2021003010A (es) 2021-05-27
ES2935705T3 (es) 2023-03-09
SI3849976T1 (sl) 2023-03-31
ZA202100976B (en) 2022-08-31
HRP20230067T1 (hr) 2023-03-17
KR20210061338A (ko) 2021-05-27
AU2019338236B2 (en) 2025-01-09
BR112021004661A2 (pt) 2021-06-01

Similar Documents

Publication Publication Date Title
JP5435946B2 (ja) 疾患を処置するためのヘッジホッグ経路アンタゴニスト
KR102712565B1 (ko) Gabaa 수용체 리간드
JP2016525547A (ja) 神経保護性の二環式化合物ならびに自閉症スペクトラム障害および神経発達障害の治療におけるそれらの使用方法
CN104703603A (zh) 新用途
Matuszewich et al. Partial antagonism of 8-OH-DPAT'S effects on male rat sexual behavior with a D2, but not a 5-HT1A, antagonist
McMahon et al. Antagonism of 5-hydroxytryptamine4 receptors attenuates hyperactivity induced by cocaine: putative role for 5-hydroxytryptamine4 receptors in the nucleus accumbens shell
EP3468602B1 (en) Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
US20100260772A1 (en) Methods for treating or preventing diseases associated with low bone mass
JP2020525480A (ja) 純粋な５−ｈｔ６受容体アンタゴニストの新たな使用
US20180104233A1 (en) Methods of treatment and pharmaceutical compositions using bcn057 or bcn512
Silva et al. The blockage of ventromedial hypothalamus CRF type 2 receptors impairs escape responses in the elevated T-maze
KR20240012533A (ko) 자가면역, 동종면역, 염증성 및 미토콘드리아 질환 치료용 조성물 및 이의 용도
HK40057209A (en) A gabaa receptor ligand
HK40057209B (en) A gabaa receptor ligand
AU2015363757B2 (en) Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
EA042675B1 (ru) Лиганд рецептора гамк-а
US20040224907A1 (en) Compositions and methods for reversal of drug resistance
Kargl et al. 16 th Scientific Symposium of the Austrian Pharmacological Society (APHAR)
König et al. P. 6.028 H-MR-Spectroscopy in obsessive compulsive disorder: Evidence for neuronal loss in the cingulate gyrus and the right striatum

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000